Skip to main content
. 2021 May 29;10(12):e019521. doi: 10.1161/JAHA.120.019521

Figure 6. The effects of CsA‐NP or Pitava‐NP on inflammation.

Figure 6

*P<0.05, 1‐way ANOVA. A, Ischemia‐reperfusion‒injured myocardium was subjected to flow cytometry. The number of monocytes were normalized by IS. Ly6Chigh activated monocytes were decreased in CsA/Pitava‐NP treated mice. The data are mean±SD (n=4 per group). *P<0.05, **P<0.01, 1‐way ANOVA. B, IL‐1β protein levels measured 24 hours after reperfusion and normalized by infarct size. The horizontal lines represent mean±SD (n=5 per group). *P<0.05, **P<0.01, 1‐way ANOVA. C, Dual channel FMT imaging revealed that CsA‐NP reduced cell death (AnnexinVivo750), whereas protease activities (ProSense680) were comparable with saline group. Treatment with Pitava‐NP or CsA/Pitava‐NP reduced both Annexin750 and ProSense680 signals. The data are mean±SD (n=7–8 per group). CsA‐NP, nanoparticles containing Cyclosporine A; FMT, fluorescence molecular tomography; IL‐1β, interleukin‐1β; IR, ischemia‐reperfusion; IS, infarct size; Pitava‐NP, nanoparticles containing pitavastatin.